Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

What Was Tested

In this phase 2 trial, researchers set out to test Glucagon.

The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection.

The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

It had two arms (groups): Glucagon (experimental) and Control (no intervention).

Insulin injected without any glucagon.

The registry classes the interventions as drug.

More on the Plan

People with type 1 diabetes will come fasting in the morning to the research facility on two separate days.

Frequently collected blood sampled will be analysed for glucose, insulin and glucagon for 3.5 hours.

Who Took Part

The registry lists 9 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 0 inclusion and 5 exclusion criteria; among the exclusions: pregnant women or women trying to conceive; any chronic disease, including psychiatric illness, judged incompatible with participation in the study; unfit for participation for any reason judged by the investigators.

How the Study Was Run

Design: randomized, crossover and open-label.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Everyone knew when Glucagon was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2023-12-22 with completion listed for 2023-12-22.

It ran at 1 site in Norway.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Area under the glucose curve (time frame: From time 0 minutes to time 60 minutes).

It also tracked 5 secondary outcomes, for example Area under glucose curve, Area under insulin curve and Area under glucagon curve.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Glucagon in 9 people.

Its size is small, so on its own it can only give an early look.

It ended early (terminated); no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Glucagon compound page, all human trials.